Viola Fanfani
Research Subjects
Viola Fanfani has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- John Quackenbush
Department of Biostatistics, T.H. Chan School of Public Health, Harvard University , Boston, MA 02115
13 shared publications - Camila Miranda Lopes-Ramos
Channing Division of Network Medicine Brigham and Women's Hospital Boston Massachusetts
10 shared publications - Katherine Hoff Shutta
Harvard T.H. Chan School of Public Health
10 shared publications - Marouen Ben Guebila
Department of Biostatistics, Harvard T.H. Chan School of Public Health , Boston, MA 02115
9 shared publications - Enakshi Saha
Department of Epidemiology and Biostatistics University of South Carolina, Columbia, SC
8 shared publications - Giovanni Stracquadanio
School of Biological Sciences, The University of Edinburgh, Edinburgh, UK
8 shared publications
Latest Publications
- Open Access
Large-scale, interpretable gene regulatory network inference through biologically informed matrix factorization
Gene regulatory networks (GRNs) provide a mechanistic framework for understanding how transcription factors coordinate gene expression to establish cellular identity and phenotype. Methods that integrate gene expression with motif-derived regulatory priors and other sources of biological information have substantially advanced gene regulatory network inference by reconstructing condition-specific regulatory architecture. These approaches estimate the evidence supporting regulatory interactions and have proven remarkably successful in a wide range of biological applications. A complementary view of regulatory networks, however, seeks to estimate the effect of those interactions on gene expression itself, providing a framework in which regulatory edges can be interpreted as activating or inhibitory influences on transcription. We developed Giraffe, a biologically informed matrix factorization framework that jointly estimates transcription factor activities and gene regulatory networks by integrating gene expression, motif-based regulatory priors, and transcription factor protein-protein interactions. Giraffe estimates signed partial regulatory effects whose magnitude and sign can be interpreted as the strength and direction of transcriptional regulation. Building directly on the biological framework established by methods such as PANDA, Giraffe provides a complementary representation of gene regulatory networks that emphasizes mechanistic interpretation while remaining scalable, flexible, and computationally efficient. Across synthetic benchmarks, six human tissues, yeast transcription factor perturbation experiments, and liver hepatocellular carcinoma, Giraffe accurately reconstructs regulatory interactions while distinguishing activating from inhibitory regulation with high accuracy. The inferred networks recover known features of tissue-specific regulation, correctly classify regulatory effects in transcription factor perturbation experiments, and identify biologically coherent changes in regulatory programs associated with liver cancer. Together, these results demonstrate that estimating the direction of transcriptional regulation provides a complementary perspective on gene regulatory networks that facilitates biological interpretation and hypothesis generation.
Open AccessLarge-scale, interpretable gene regulatory network inference through biologically informed matrix factorization
Gene regulatory networks (GRNs) provide a mechanistic framework for understanding how transcription factors coordinate gene expression to establish cellular identity and phenotype. Methods that integrate gene expression with motif-derived regulatory priors and other sources of biological information have substantially advanced gene regulatory network inference by reconstructing condition-specific regulatory architecture. These approaches estimate the evidence supporting regulatory interactions and have proven remarkably successful in a wide range of biological applications. A complementary view of regulatory networks, however, seeks to estimate the effect of those interactions on gene expression itself, providing a framework in which regulatory edges can be interpreted as activating or inhibitory influences on transcription. We developed Giraffe, a biologically informed matrix factorization framework that jointly estimates transcription factor activities and gene regulatory networks by integrating gene expression, motif-based regulatory priors, and transcription factor protein-protein interactions. Giraffe estimates signed partial regulatory effects whose magnitude and sign can be interpreted as the strength and direction of transcriptional regulation. Building directly on the biological framework established by methods such as PANDA, Giraffe provides a complementary representation of gene regulatory networks that emphasizes mechanistic interpretation while remaining scalable, flexible, and computationally efficient. Across synthetic benchmarks, six human tissues, yeast transcription factor perturbation experiments, and liver hepatocellular carcinoma, Giraffe accurately reconstructs regulatory interactions while distinguishing activating from inhibitory regulation with high accuracy. The inferred networks recover known features of tissue-specific regulation, correctly classify regulatory effects in transcription factor perturbation experiments, and identify biologically coherent changes in regulatory programs associated with liver cancer. Together, these results demonstrate that estimating the direction of transcriptional regulation provides a complementary perspective on gene regulatory networks that facilitates biological interpretation and hypothesis generation.
- Open Access
- 11 June 2026
- Published by Wiley in Current Protocols
- Vol. 6 (6) , e70396
Deploying a JupyterHub Server for Academic Research Using Netbooks as an Example
Jupyter Notebooks have transformed the way we conduct computational research thanks to a versatile platform that combines code, annotations, plots, and a lightweight format that enables versioning. However, steps for installing dependencies and downloading data for a specific notebook may require significant time and failure to establish identical environments can compromise reproducibility of environments. Deploying a JupyterHub server not only provides a containerized environment for each notebook to ensure fast execution and exact reproducibility but also provides a computational engine that makes these applications available from any device. By providing all the steps for deploying a JupyterHub server, and providing our experience deploying and maintaining Netbooks, a server for academic investigations in network biology, we want to encourage other groups to deploy JupyterHub servers for their own computational work and to recognize their value in improving reproducibility, accelerating manuscript review, and supporting education. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol : Setting up a JupyterHub server Support Protocol 1 : Compiling a collection of Jupyter Notebooks Support Protocol 2 : Securing HTTPS access Support Protocol 3 : Adding parameters for JupyterHub Support Protocol 4 : Data management for JupyterHub Support Protocol 5 : Customizing the website homepage Support Protocol 6 : Importing/Exporting conda environments Alternate Protocol : Running a JupyterHub server as a virtual machine
- 11 June 2026
- Published by Wiley in Current Protocols
- Vol. 6 (6) , e70396
Open AccessDeploying a JupyterHub Server for Academic Research Using Netbooks as an Example
Jupyter Notebooks have transformed the way we conduct computational research thanks to a versatile platform that combines code, annotations, plots, and a lightweight format that enables versioning. However, steps for installing dependencies and downloading data for a specific notebook may require significant time and failure to establish identical environments can compromise reproducibility of environments. Deploying a JupyterHub server not only provides a containerized environment for each notebook to ensure fast execution and exact reproducibility but also provides a computational engine that makes these applications available from any device. By providing all the steps for deploying a JupyterHub server, and providing our experience deploying and maintaining Netbooks, a server for academic investigations in network biology, we want to encourage other groups to deploy JupyterHub servers for their own computational work and to recognize their value in improving reproducibility, accelerating manuscript review, and supporting education. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol : Setting up a JupyterHub server Support Protocol 1 : Compiling a collection of Jupyter Notebooks Support Protocol 2 : Securing HTTPS access Support Protocol 3 : Adding parameters for JupyterHub Support Protocol 4 : Data management for JupyterHub Support Protocol 5 : Customizing the website homepage Support Protocol 6 : Importing/Exporting conda environments Alternate Protocol : Running a JupyterHub server as a virtual machine
- Open Access
Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma multiforme treatment resistance in females
Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor that is notoriously resistant to treatment, with an average survival time of 17 months. While the overall outcome is poor for both males and females, sex differences in GBM incidence and outcome suggest sex-specific biological mechanisms underlie tumorigenesis. In contrast, low-grade glioma (LGG) is a less aggressive brain tumor that tends to have a better prognosis and a longer survival time. Methods: To understand mechanisms contributing to treatment resistance in GBM in both males and females, we inferred gene regulatory networks (GRNs) for males and females with LGG and GBM using RNA-seq data from The Cancer Genome Atlas (TCGA). We analyzed these to identify both sex-specific and sex-stratified gene regulation in GBM. Results: We found few sex-specific differences in gene regulation in individuals with LGG, consistent with the lack of evidence for significant clinical endpoints dependent on sex. However, in GBM-we found sex-specific differential targeting of several pathways, including hypoxia and related pathways (carbohydrate metabolism, innate immune processes, and extracellular matrix pathways) known to be dysregulated in hypoxic conditions. In comparing between individuals with GBM, we found that females exhibited a greater degree of co-regulation between hypoxia with the aforementioned downstream pathways than did males. Conclusions: Our results suggest that dysregulation of hypoxia-related pathways in GBM plays a female-specific role in resistance to treatment and overall outcomes.
Open AccessGene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma multiforme treatment resistance in females
Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor that is notoriously resistant to treatment, with an average survival time of 17 months. While the overall outcome is poor for both males and females, sex differences in GBM incidence and outcome suggest sex-specific biological mechanisms underlie tumorigenesis. In contrast, low-grade glioma (LGG) is a less aggressive brain tumor that tends to have a better prognosis and a longer survival time. Methods: To understand mechanisms contributing to treatment resistance in GBM in both males and females, we inferred gene regulatory networks (GRNs) for males and females with LGG and GBM using RNA-seq data from The Cancer Genome Atlas (TCGA). We analyzed these to identify both sex-specific and sex-stratified gene regulation in GBM. Results: We found few sex-specific differences in gene regulation in individuals with LGG, consistent with the lack of evidence for significant clinical endpoints dependent on sex. However, in GBM-we found sex-specific differential targeting of several pathways, including hypoxia and related pathways (carbohydrate metabolism, innate immune processes, and extracellular matrix pathways) known to be dysregulated in hypoxic conditions. In comparing between individuals with GBM, we found that females exhibited a greater degree of co-regulation between hypoxia with the aforementioned downstream pathways than did males. Conclusions: Our results suggest that dysregulation of hypoxia-related pathways in GBM plays a female-specific role in resistance to treatment and overall outcomes.
- Open Access
Sex differences in gene regulation and its impact on cancer incidence
Sex differences in the incidence rates of many cancer types are well-documented. While differences in lifestyle, environmental exposures, and hormone levels can influence disease risk and incidence, there is limited understanding of how cancer driver genes are differentially regulated between males and females in normal tissues, and how these differences may contribute to the observed sex differences in cancer epidemiology. We studied 8,279 gene regulatory networks across 29 non-cancerous tissues in the GTEx dataset, referred here as normal tissues. Using network centrality measures, we compared the networks between males and females, focusing on interactions between 644 transcription factors and 476 cancer genes (COSMIC Cancer Gene Census). Cancer genes were differentially targeted by transcription factors in males and females across normal tissues. We found an overrepresentation of sex-biased cancer genes on the X chromosome, particularly among genes escaping X chromosome inactivation, with higher regulatory targeting of tumor suppressor genes in females compared to males. Key signaling pathways, including WNT, NOTCH, and p53, showed differential transcriptional targeting by sex. We observed higher targeting of cancer-related pathways in females for tissues that have higher tumor incidence in females (breast, lung, and thyroid) and higher targeting in males for tissues with increased tumor incidence in males (stomach, colon, and liver). Sex-biased transcription factors that were consistently observed across multiple tissues are enriched for sex hormone response elements in their promoters. Our findings showed that normal tissues have sex-biased regulation of genes implicated in tumorigenesis, helping to explain the molecular basis of sex differences observed in cancer incidence rates and in identifying targets for cancer prevention in a sex-aware manner.
Open AccessSex differences in gene regulation and its impact on cancer incidence
Sex differences in the incidence rates of many cancer types are well-documented. While differences in lifestyle, environmental exposures, and hormone levels can influence disease risk and incidence, there is limited understanding of how cancer driver genes are differentially regulated between males and females in normal tissues, and how these differences may contribute to the observed sex differences in cancer epidemiology. We studied 8,279 gene regulatory networks across 29 non-cancerous tissues in the GTEx dataset, referred here as normal tissues. Using network centrality measures, we compared the networks between males and females, focusing on interactions between 644 transcription factors and 476 cancer genes (COSMIC Cancer Gene Census). Cancer genes were differentially targeted by transcription factors in males and females across normal tissues. We found an overrepresentation of sex-biased cancer genes on the X chromosome, particularly among genes escaping X chromosome inactivation, with higher regulatory targeting of tumor suppressor genes in females compared to males. Key signaling pathways, including WNT, NOTCH, and p53, showed differential transcriptional targeting by sex. We observed higher targeting of cancer-related pathways in females for tissues that have higher tumor incidence in females (breast, lung, and thyroid) and higher targeting in males for tissues with increased tumor incidence in males (stomach, colon, and liver). Sex-biased transcription factors that were consistently observed across multiple tissues are enriched for sex hormone response elements in their promoters. Our findings showed that normal tissues have sex-biased regulation of genes implicated in tumorigenesis, helping to explain the molecular basis of sex differences observed in cancer incidence rates and in identifying targets for cancer prevention in a sex-aware manner.
- Open Access
- 29 September 2025
- Published by Springer Nature in Biology of Sex Differences
- Vol. 16 (1) , 1-17
Multi-omics protein signaling networks identify sex-specific therapeutic candidates in lung adenocarcinoma
Background: Lung adenocarcinoma shows distinct differences between males and females in incidence, prognosis, and treatment response, suggesting unique molecular mechanisms that remain underexplored. This study aims to identify sex-specific molecular signatures and therapeutic targets in lung adenocarcinoma using multi-omics approaches to inform personalized treatment strategies. Methods: We conducted an integrative analysis of transcriptomic and proteomic data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and The Cancer Genome Atlas (TCGA) datasets, comparing male and female lung adenocarcinoma profiles. Transcription factor activity was assessed using TIGER on gene expression data, while kinase activity was evaluated with PTM-SEA on proteomic data. These results were combined to build a kinase-transcription factor signaling network. Potential sex-specific drugs were identified using the PRISM drug screening database. Results: The analysis revealed significant sex-based differences in transcription factor and kinase activity. Notably, NR3C1, AR, and AURKA exhibited sex-biased expression and activity. The constructed signaling network highlighted druggable pathways linked to cancer-related processes, with distinct profiles in males and females. PRISM screening identified glucocorticoid receptor agonists and aurora kinase inhibitors as promising sex-specific therapeutic candidates. Conclusions: Our findings underscore the importance of considering sex differences in lung adenocarcinoma molecular profiles. The integration of transcriptomic and proteomic data reveals sex-specific pathways and potential therapies, paving the way for personalized treatment approaches tailored to male and female patients.
- 29 September 2025
- Published by Springer Nature in Biology of Sex Differences
- Vol. 16 (1) , 1-17
Open AccessMulti-omics protein signaling networks identify sex-specific therapeutic candidates in lung adenocarcinoma
Background: Lung adenocarcinoma shows distinct differences between males and females in incidence, prognosis, and treatment response, suggesting unique molecular mechanisms that remain underexplored. This study aims to identify sex-specific molecular signatures and therapeutic targets in lung adenocarcinoma using multi-omics approaches to inform personalized treatment strategies. Methods: We conducted an integrative analysis of transcriptomic and proteomic data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and The Cancer Genome Atlas (TCGA) datasets, comparing male and female lung adenocarcinoma profiles. Transcription factor activity was assessed using TIGER on gene expression data, while kinase activity was evaluated with PTM-SEA on proteomic data. These results were combined to build a kinase-transcription factor signaling network. Potential sex-specific drugs were identified using the PRISM drug screening database. Results: The analysis revealed significant sex-based differences in transcription factor and kinase activity. Notably, NR3C1, AR, and AURKA exhibited sex-biased expression and activity. The constructed signaling network highlighted druggable pathways linked to cancer-related processes, with distinct profiles in males and females. PRISM screening identified glucocorticoid receptor agonists and aurora kinase inhibitors as promising sex-specific therapeutic candidates. Conclusions: Our findings underscore the importance of considering sex differences in lung adenocarcinoma molecular profiles. The integration of transcriptomic and proteomic data reveals sex-specific pathways and potential therapies, paving the way for personalized treatment approaches tailored to male and female patients.
- Open Access
Identifying Sex Differences in Lung Adenocarcinoma Using Multi-Omics Integrative Protein Signaling Networks
Lung adenocarcinoma (LUAD) exhibits differences between the sexes in incidence, prognosis, and therapy, suggesting underexplored molecular mechanisms. We conducted an integrative multi-omics analysis using the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and The Cancer Genome Atlas (TCGA) datasets to contrast transcriptomes and proteomes between sexes. We used TIGER to analyze TCGA-LUAD expression data and found sex-biased activity of transcription factors (TFs); we used PTM-SEA with CPTAC-LUAD proteomics data and found sex-biased kinase activity. We combined these to construct a kinase-TF signaling network and discovered druggable pathways linked to cancer-related processes. We also found significant sex biases in clinically relevant TFs and kinases, including NR3C1, AR, and AURKA. Using the PRISM drug screening database, we identified potential sex-specific drugs, such as glucocorticoid receptor agonists and aurora kinase inhibitors. Our findings emphasize the importance of considering sex and using multi-omics network methods to discover personalized cancer therapies.
Open AccessIdentifying Sex Differences in Lung Adenocarcinoma Using Multi-Omics Integrative Protein Signaling Networks
Lung adenocarcinoma (LUAD) exhibits differences between the sexes in incidence, prognosis, and therapy, suggesting underexplored molecular mechanisms. We conducted an integrative multi-omics analysis using the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and The Cancer Genome Atlas (TCGA) datasets to contrast transcriptomes and proteomes between sexes. We used TIGER to analyze TCGA-LUAD expression data and found sex-biased activity of transcription factors (TFs); we used PTM-SEA with CPTAC-LUAD proteomics data and found sex-biased kinase activity. We combined these to construct a kinase-TF signaling network and discovered druggable pathways linked to cancer-related processes. We also found significant sex biases in clinically relevant TFs and kinases, including NR3C1, AR, and AURKA. Using the PRISM drug screening database, we identified potential sex-specific drugs, such as glucocorticoid receptor agonists and aurora kinase inhibitors. Our findings emphasize the importance of considering sex and using multi-omics network methods to discover personalized cancer therapies.
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 14
Reproducible processing of TCGA regulatory networks
Background: Technological advances in sequencing and computation have allowed deep exploration of the molecular basis of diseases. Biological networks have proven to be a valuable framework for analyzing omics data and modeling regulatory interactions between genes and proteins. Large collaborative projects, such as The Cancer Genome Atlas (TCGA), have provided a rich resource for building and validating new computational methods, resulting in a plethora of open-source software for downloading, preprocessing, and analyzing those data. However, for an end-to-end analysis of regulatory networks, a coherent and reusable workflow is essential to integrate all relevant packages into a robust pipeline. Findings: We developed tcga-data-nf, a Nextflow workflow that allows users to reproducibly infer regulatory networks from the thousands of samples in TCGA using a single command. The workflow can be divided into 3 main steps: multiomic data, such as RNA sequencing and methylation, are (i) downloaded, (ii) preprocessed, and (iii) analyzed to infer regulatory network models with the Network Zoo. The workflow is powered by the NetworkDataCompanion R package, a standalone collection of functions for managing, mapping, and filtering TCGA data. Here, we demonstrate how the pipeline can be used to investigate the differences between colon cancer subtypes attributed to epigenetic mechanisms. Lastly, we provide a database of pregenerated networks for the 10 most common cancer types that can be readily accessed by the public. Conclusions: tcga-data-nf is a complete, yet flexible and extensible, framework that enables the reproducible inference and analysis of cancer regulatory networks, bridging a gap in the current universe of software tools for analyzing TCGA data.
- 6 January 2025
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 14
Open AccessReproducible processing of TCGA regulatory networks
Background: Technological advances in sequencing and computation have allowed deep exploration of the molecular basis of diseases. Biological networks have proven to be a valuable framework for analyzing omics data and modeling regulatory interactions between genes and proteins. Large collaborative projects, such as The Cancer Genome Atlas (TCGA), have provided a rich resource for building and validating new computational methods, resulting in a plethora of open-source software for downloading, preprocessing, and analyzing those data. However, for an end-to-end analysis of regulatory networks, a coherent and reusable workflow is essential to integrate all relevant packages into a robust pipeline. Findings: We developed tcga-data-nf, a Nextflow workflow that allows users to reproducibly infer regulatory networks from the thousands of samples in TCGA using a single command. The workflow can be divided into 3 main steps: multiomic data, such as RNA sequencing and methylation, are (i) downloaded, (ii) preprocessed, and (iii) analyzed to infer regulatory network models with the Network Zoo. The workflow is powered by the NetworkDataCompanion R package, a standalone collection of functions for managing, mapping, and filtering TCGA data. Here, we demonstrate how the pipeline can be used to investigate the differences between colon cancer subtypes attributed to epigenetic mechanisms. Lastly, we provide a database of pregenerated networks for the 10 most common cancer types that can be readily accessed by the public. Conclusions: tcga-data-nf is a complete, yet flexible and extensible, framework that enables the reproducible inference and analysis of cancer regulatory networks, bridging a gap in the current universe of software tools for analyzing TCGA data.
- Open Access
Reproducible processing of TCGA regulatory networks
Background: Technological advances in sequencing and computation have allowed deep exploration of the molecular basis of diseases. Biological networks have proven to be a useful framework for interrogating omics data and modeling regulatory gene and protein interactions. Large collaborative projects, such as The Cancer Genome Atlas (TCGA), have provided a rich resource for building and validating new computational methods resulting in a plethora of open-source software for downloading, pre-processing, and analyzing those data. However, for an end-to-end analysis of regulatory networks a coherent and reusable workflow is essential to integrate all relevant packages into a robust pipeline. Findings: We developed tcga-data-nf, a Nextflow workflow that allows users to reproducibly infer regulatory networks from the thousands of samples in TCGA using a single command. The workflow can be divided into three main steps: multi-omics data, such as RNA-seq and methylation, are downloaded, preprocessed, and lastly used to infer regulatory network models with the netZoo software tools. The workflow is powered by the NetworkDataCompanion R package, a standalone collection of functions for managing, mapping, and filtering TCGA data. Here we show how the pipeline can be used to study the differences between colon cancer subtypes that could be explained by epigenetic mechanisms. Lastly, we provide pre-generated networks for the 10 most common cancer types that can be readily accessed. Conclusions: tcga-data-nf is a complete yet flexible and extensible framework that enables the reproducible inference and analysis of cancer regulatory networks, bridging a gap in the current universe of software tools.
Open AccessReproducible processing of TCGA regulatory networks
Background: Technological advances in sequencing and computation have allowed deep exploration of the molecular basis of diseases. Biological networks have proven to be a useful framework for interrogating omics data and modeling regulatory gene and protein interactions. Large collaborative projects, such as The Cancer Genome Atlas (TCGA), have provided a rich resource for building and validating new computational methods resulting in a plethora of open-source software for downloading, pre-processing, and analyzing those data. However, for an end-to-end analysis of regulatory networks a coherent and reusable workflow is essential to integrate all relevant packages into a robust pipeline. Findings: We developed tcga-data-nf, a Nextflow workflow that allows users to reproducibly infer regulatory networks from the thousands of samples in TCGA using a single command. The workflow can be divided into three main steps: multi-omics data, such as RNA-seq and methylation, are downloaded, preprocessed, and lastly used to infer regulatory network models with the netZoo software tools. The workflow is powered by the NetworkDataCompanion R package, a standalone collection of functions for managing, mapping, and filtering TCGA data. Here we show how the pipeline can be used to study the differences between colon cancer subtypes that could be explained by epigenetic mechanisms. Lastly, we provide pre-generated networks for the 10 most common cancer types that can be readily accessed. Conclusions: tcga-data-nf is a complete yet flexible and extensible framework that enables the reproducible inference and analysis of cancer regulatory networks, bridging a gap in the current universe of software tools.
- Open Access
Selective loss of Y chromosomes in lung adenocarcinoma modulates the tumor immune environment through cancer/testis antigens
There is increasing recognition that the allosomes, X and Y, play an important role in health and disease beyond the determination of biological sex. A loss of the Y chromosome (LOY) occurs in most solid tumors in males and is often associated with worse survival, suggesting that LOY may give tumor cells a growth or survival advantage. We here use an expression-based continuous measure of LOY that allows us to investigate LOY in lung adenocarcinoma (LUAD) using both bulk and single-cell expression data. We find evidence suggesting that LOY affects the tumor immune environment by altering cancer/testis antigen expression and consequently facilitating tumor immune evasion, also reflected in inferred gene regulatory networks. In immunotherapy data, we further show that LOY and changes in expression of particular cancer/testis antigens are associated with response to pembrolizumab treatment and outcome. This computational study provides new insights into the mechanisms behind LOY in LUAD and a powerful biomarker for predicting immunotherapy response in LUAD tumors in males.
Open AccessSelective loss of Y chromosomes in lung adenocarcinoma modulates the tumor immune environment through cancer/testis antigens
There is increasing recognition that the allosomes, X and Y, play an important role in health and disease beyond the determination of biological sex. A loss of the Y chromosome (LOY) occurs in most solid tumors in males and is often associated with worse survival, suggesting that LOY may give tumor cells a growth or survival advantage. We here use an expression-based continuous measure of LOY that allows us to investigate LOY in lung adenocarcinoma (LUAD) using both bulk and single-cell expression data. We find evidence suggesting that LOY affects the tumor immune environment by altering cancer/testis antigen expression and consequently facilitating tumor immune evasion, also reflected in inferred gene regulatory networks. In immunotherapy data, we further show that LOY and changes in expression of particular cancer/testis antigens are associated with response to pembrolizumab treatment and outcome. This computational study provides new insights into the mechanisms behind LOY in LUAD and a powerful biomarker for predicting immunotherapy response in LUAD tumors in males.
- Open Access
- 12 August 2024
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 34 (9) , 1397-1410
Bayesian inference of sample-specific coexpression networks
Gene regulatory networks (GRNs) are effective tools for inferring complex interactions between molecules that regulate biological processes and hence can provide insights into drivers of biological systems. Inferring coexpression networks is a critical element of GRN inference, as the correlation between expression patterns may indicate that genes are coregulated by common factors. However, methods that estimate coexpression networks generally derive an aggregate network representing the mean regulatory properties of the population and so fail to fully capture population heterogeneity. Bayesian optimized networks obtained by assimilating omic data (BONOBO) is a scalable Bayesian model for deriving individual sample-specific coexpression matrices that recognizes variations in molecular interactions across individuals. For each sample, BONOBO assumes a Gaussian distribution on the log-transformed centered gene expression and a conjugate prior distribution on the sample-specific coexpression matrix constructed from all other samples in the data. Combining the sample-specific gene coexpression with the prior distribution, BONOBO yields a closed-form solution for the posterior distribution of the sample-specific coexpression matrices, thus allowing the analysis of large data sets. We demonstrate BONOBO's utility in several contexts, including analyzing gene regulation in yeast transcription factor knockout studies, the prognostic significance of miRNA–mRNA interaction in human breast cancer subtypes, and sex differences in gene regulation within human thyroid tissue. We find that BONOBO outperforms other methods that have been used for sample-specific coexpression network inference and provides insight into individual differences in the drivers of biological processes.
- 12 August 2024
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 34 (9) , 1397-1410
Open AccessBayesian inference of sample-specific coexpression networks
Gene regulatory networks (GRNs) are effective tools for inferring complex interactions between molecules that regulate biological processes and hence can provide insights into drivers of biological systems. Inferring coexpression networks is a critical element of GRN inference, as the correlation between expression patterns may indicate that genes are coregulated by common factors. However, methods that estimate coexpression networks generally derive an aggregate network representing the mean regulatory properties of the population and so fail to fully capture population heterogeneity. Bayesian optimized networks obtained by assimilating omic data (BONOBO) is a scalable Bayesian model for deriving individual sample-specific coexpression matrices that recognizes variations in molecular interactions across individuals. For each sample, BONOBO assumes a Gaussian distribution on the log-transformed centered gene expression and a conjugate prior distribution on the sample-specific coexpression matrix constructed from all other samples in the data. Combining the sample-specific gene coexpression with the prior distribution, BONOBO yields a closed-form solution for the posterior distribution of the sample-specific coexpression matrices, thus allowing the analysis of large data sets. We demonstrate BONOBO's utility in several contexts, including analyzing gene regulation in yeast transcription factor knockout studies, the prognostic significance of miRNA–mRNA interaction in human breast cancer subtypes, and sex differences in gene regulation within human thyroid tissue. We find that BONOBO outperforms other methods that have been used for sample-specific coexpression network inference and provides insight into individual differences in the drivers of biological processes.